Sign in
TENX Stock Price, Chart, Stats & News
Tenax Therapeutics, Inc.
Save
Tenax Therapeutics, Inc. (TENX) does not currently pay a dividend.
48.81M
Market cap
–
Current P/E
0.30x
Forward P/E
TENX chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -50.47% |
ROE | -51.83% |
D/E | – |
Interest coverage ratio | – |
TENX valuation
P/E | – |
P/S | – |
P/B | 6.02x |
P/CF | -16.32x |
P/FCF | -7.16x |
P/OCF | -16.32x |
PEG | 0.60x |
EV multiple | – |
About
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension.
Similar securities
Based on sector and market capitalization
Report issue